|
||||||
|
Datasets with Targeted_therapy |
 The duplicated datasets indicate that this dataset include both pre-treatment and post-treatment samples, and partial analyses were conducted on each of the two timepoints. The dataset page shows more informations, and the analysis results of this dataset. |
| Dataset | Source | Tissue | Cancer type level1 | Cancer type level2 | Drug type | Regimen | Timepoint |
GSE189460 | patients | Bone marrow aspirate | Multiple myeloma | Multiple myeloma (MM) | Targeted therapy | bortezomib + melphalan + prednisolone | pre |
GSE161801_PI | patients | Bone marrow aspirate | Multiple myeloma | Refractory multiple myeloma (MM) | Targeted therapy | carfilzomib + dexamethasone | post |
GSE161801_PI | patients | Bone marrow aspirate | Multiple myeloma | Refractory multiple myeloma (MM) | Targeted therapy | carfilzomib + dexamethasone | pre |
GSE139386 | H3122 cell line | Cell line | Lung cancer | EML4-ALK fusion-positive non-small cell lung cancer (NSCLC) | Targeted therapy | ceritinib | NA |
GSE161195 | patients | Bone marrow aspirate | Multiple myeloma | Refractory multiple myeloma (MM) | Targeted therapy | DARA-KRD (daratumumab + carfilzomib + lenalidomide + dexamethasone) | post |
GSE161195 | patients | Bone marrow aspirate | Multiple myeloma | Refractory multiple myeloma (MM) | Targeted therapy | DARA-KRD (daratumumab + carfilzomib + lenalidomide + dexamethasone) | pre |
GSE158457 | PDX cells | Cell line | Acute lymphoblastic leukemia | T-cell acute lymphoblastic leukemia (ALL) | Targeted therapy | dasatinib | NA |
GSE168668 | LNCaP cell line | Cell line | Prostate cancer | Prostate cancer | Targeted therapy | enzalutamide | NA |
GSE149214 | PC9 cell line | Cell line | Lung cancer | EGFR-mutated non-small cell lung cancer (NSCLC) | Targeted therapy | erlotinib | NA |
GSE162117 | patients | Peripheral blood mononuclear cells | Acute myeloid leukemia | Tefractory acute myeloid leukemia (AML) | Targeted therapy | ficlatuzumab | post |
GSE162117 | patients | Peripheral blood mononuclear cells | Acute myeloid leukemia | Tefractory acute myeloid leukemia (AML) | Targeted therapy | ficlatuzumab | pre |
GSE199333 | patients | Bone marrow aspirate | Acute myeloid leukemia | Primary FLT3-ITD-mutated acute myeloid leukemia (AML) | Targeted therapy | gilteritinib | post |
GSE199333 | patients | Bone marrow aspirate | Acute myeloid leukemia | Primary FLT3-ITD-mutated acute myeloid leukemia (AML) | Targeted therapy | gilteritinib | pre |
GSE111014 | patients | Peripheral blood mononuclear cells | Chronic lymphocytic leukemia | Chronic lymphocytic leukemia (CLL) | Targeted therapy | ibrutinib | post |
GSE111014 | patients | Peripheral blood mononuclear cells | Chronic lymphocytic leukemia | Chronic lymphocytic leukemia (CLL) | Targeted therapy | ibrutinib | pre |
GSE152469 | patients | Peripheral blood mononuclear cells | Chronic lymphocytic leukemia | Chronic lymphocytic leukemia (CLL) | Targeted therapy | ibrutinib | NA |
GSE131984_JQ1 | SUM159 cell line | Cell line | Breast cancer | Triple-negative breast cancer (TNBC) | Targeted therapy | JQ1 | NA |
GSE131984_JQ1Pac | SUM159 cell line | Cell line | Breast cancer | Triple-negative breast cancer (TNBC) | Targeted therapy | JQ1 + paclitaxel | NA |
GSE131984_JQ1Pal | SUM159 cell line | Cell line | Breast cancer | Triple-negative breast cancer (TNBC) | Targeted therapy | JQ1 + palbociclib | NA |
GSE104987 | MCF7 cell line | Cell line | Breast cancer | ER+ breast cancer | Targeted therapy | KDM5-C70 | NA |
GSE131984_Pal | SUM159 cell line | Cell line | Breast cancer | Triple-negative breast cancer (TNBC) | Targeted therapy | palbociclib | NA |
GSE108397 | 451Lu cell line | Cell line | Melanoma | Melanoma | Targeted therapy | PLX-4720 | NA |
GSE161801_IMiD | patients | Bone marrow aspirate | Multiple myeloma | Refractory multiple myeloma (MM) | Targeted therapy | pomalidomide + dexamethasone OR lenalidomide + dexamethasone | post |
GSE161801_IMiD | patients | Bone marrow aspirate | Multiple myeloma | Refractory multiple myeloma (MM) | Targeted therapy | pomalidomide + dexamethasone OR lenalidomide + dexamethasone | pre |
GSE175716 | PDX | Tumor tissue | Liver cancer | Advanced hepatocellular carcinoma | Targeted therapy | sorafenib | NA |
GSE115251 | Kelly cell line | Cell line | Neuroblastoma | Neuroblastoma | Targeted therapy | TAE684 | NA |
GSE164897_Vem | A375 cell line | Cell line | Melanoma | BRAFV600E-mutant melanoma | Targeted therapy | vemurafenib | NA |
GSE164897_VemCob | A375 cell line | Cell line | Melanoma | BRAFV600E-mutant melanoma | Targeted therapy | vemurafenib + combimetinib | NA |
GSE164897_VemTra | A375 cell line | Cell line | Melanoma | B+E2:E57RAFV600E-mutant melanoma | Targeted therapy | vemurafenib + trametinib | NA |
Copyright 2022-Present -The University of Texas Health Science Center at Houston |